!!
Normal on-treatment #ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis #B
https://www.journal-of-hepatology.eu/article/S0168-8278(18)32055-5/fulltext
21,182 CHB patients (10,437 with and 10,745 without ALT-N at 12 months after antiviral treatment) were identified and followed for 4.0±1.7 years. Patients with and without ALT-N differed in baseline ALT (58 vs 61 U/L), HBV DNA (4.9 vs. 5.1 log10 IU/mL) and cirrhosis status (8.8% vs. 10.5%). 627 (3.0%) patients developed composite hepatic events. Compared to no ALT-N, ALT-N at 3, 6, 9 and 12 months reduced the risk of hepatic events, after adjustment for baseline ALT and other important co-variates, with adjusted hazard ratios (95% CI) of 0.61 (0.49-0.77), 0.55 (0.45-0.67), 0.54 (0.44-0.65) and 0.51 (0.42-0.61) respectively (all P<0.001). The cumulative incidence (95% CI) of composite hepatic events at 6 years was 3.51% (3.06%-4.02%) in ALT-N and 5.70% (5.15%-6.32%) in no ALT-N group (P<0.001).
Conclusions
Normal on-treatment ALT can be translated into improved clinical outcomes in CHB patients receiving NA treatment.
Normal on-treatment #ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis #B
https://www.journal-of-hepatology.eu/article/S0168-8278(18)32055-5/fulltext
21,182 CHB patients (10,437 with and 10,745 without ALT-N at 12 months after antiviral treatment) were identified and followed for 4.0±1.7 years. Patients with and without ALT-N differed in baseline ALT (58 vs 61 U/L), HBV DNA (4.9 vs. 5.1 log10 IU/mL) and cirrhosis status (8.8% vs. 10.5%). 627 (3.0%) patients developed composite hepatic events. Compared to no ALT-N, ALT-N at 3, 6, 9 and 12 months reduced the risk of hepatic events, after adjustment for baseline ALT and other important co-variates, with adjusted hazard ratios (95% CI) of 0.61 (0.49-0.77), 0.55 (0.45-0.67), 0.54 (0.44-0.65) and 0.51 (0.42-0.61) respectively (all P<0.001). The cumulative incidence (95% CI) of composite hepatic events at 6 years was 3.51% (3.06%-4.02%) in ALT-N and 5.70% (5.15%-6.32%) in no ALT-N group (P<0.001).
Conclusions
Normal on-treatment ALT can be translated into improved clinical outcomes in CHB patients receiving NA treatment.